OBJECTIVES: The goal of this study was to determine if biomarkers of subclinical myocardial injury and hemodynamic stress identify asymptomatic individuals with left ventricular hypertrophy (LVH) at higher risk for heart failure (HF) and death. BACKGROUND: The interaction between LVH, low but detectable cardiac troponin T (cTnT), and elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) on cardiovascular (CV) outcomes in the general population is unknown. METHODS: Participants in the Dallas Heart Study without clinical HF, LV dysfunction, or chronic kidney disease underwent measurement of LV mass by magnetic resonance imaging (MRI), cTnT by highly sensitive assay, and NT-proBNP analysis (n = 2,413). Subjects were stratified according to LVH and by detectable cTnT (≥3 pg/ml) and increased NT-proBNP (>75th age- and sex-specific percentile) levels. For each analysis, participants were categorized into groups based on the presence (+) or absence (-) of LVH and biomarker levels above (+) or below (-) the predefined threshold. RESULTS: Nine percent of participants were LVH+, 25% cTnT+, and 24% NT-proBNP+. Those LVH+ and cTnT+ and/or NT-proBNP+ (n = 144) were older and more likely to be male, with a greater risk factor burden and more severe LVH compared with those who were LVH+ biomarker- (p < 0.01 for each). The cumulative incidence of HF or CV death over 8 years among LVH+ cTnT+ was 21% versus 1% (LVH- cTnT-), 4% (LVH- cTnT+), and 6% (LVH+ cTnT-) (p < 0.0001). The interactions between LVH and cTnT (p(interaction) = 0.0005) and LVH and NT-proBNP (p(interaction) = 0.014) were highly significant. Individuals who were LVH+ and either cTnT+ or NT-proBNP+ remained at >4-fold higher risk for HF or CV death after multivariable adjustment for CV risk factors, renal function, and LV mass compared with those who were LVH- biomarker-. CONCLUSIONS: Minimal elevations in biomarkers of subclinical cardiac injury and hemodynamic stress modify the association of LVH with adverse outcomes, identifying a malignant subphenotype of LVH with high risk for progression to HF and CV death.
OBJECTIVES: The goal of this study was to determine if biomarkers of subclinical myocardial injury and hemodynamic stress identify asymptomatic individuals with left ventricular hypertrophy (LVH) at higher risk for heart failure (HF) and death. BACKGROUND: The interaction between LVH, low but detectable cardiac troponin T (cTnT), and elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) on cardiovascular (CV) outcomes in the general population is unknown. METHODS:Participants in the Dallas Heart Study without clinical HF, LV dysfunction, or chronic kidney disease underwent measurement of LV mass by magnetic resonance imaging (MRI), cTnT by highly sensitive assay, and NT-proBNP analysis (n = 2,413). Subjects were stratified according to LVH and by detectable cTnT (≥3 pg/ml) and increased NT-proBNP (>75th age- and sex-specific percentile) levels. For each analysis, participants were categorized into groups based on the presence (+) or absence (-) of LVH and biomarker levels above (+) or below (-) the predefined threshold. RESULTS: Nine percent of participants were LVH+, 25% cTnT+, and 24% NT-proBNP+. Those LVH+ and cTnT+ and/or NT-proBNP+ (n = 144) were older and more likely to be male, with a greater risk factor burden and more severe LVH compared with those who were LVH+ biomarker- (p < 0.01 for each). The cumulative incidence of HF or CV death over 8 years among LVH+ cTnT+ was 21% versus 1% (LVH- cTnT-), 4% (LVH- cTnT+), and 6% (LVH+ cTnT-) (p < 0.0001). The interactions between LVH and cTnT (p(interaction) = 0.0005) and LVH and NT-proBNP (p(interaction) = 0.014) were highly significant. Individuals who were LVH+ and either cTnT+ or NT-proBNP+ remained at >4-fold higher risk for HF or CV death after multivariable adjustment for CV risk factors, renal function, and LV mass compared with those who were LVH- biomarker-. CONCLUSIONS: Minimal elevations in biomarkers of subclinical cardiac injury and hemodynamic stress modify the association of LVH with adverse outcomes, identifying a malignant subphenotype of LVH with high risk for progression to HF and CV death.
Authors: S Hinan Ahmed; Leslie L Clark; Weems R Pennington; Carson S Webb; D Dirk Bonnema; Amy H Leonardi; Catherine D McClure; Francis G Spinale; Michael R Zile Journal: Circulation Date: 2006-04-24 Impact factor: 29.690
Authors: Lisa C Costello-Boerrigter; Guido Boerrigter; Margaret M Redfield; Richard J Rodeheffer; Lynn H Urban; Douglas W Mahoney; Steven J Jacobsen; Denise M Heublein; John C Burnett Journal: J Am Coll Cardiol Date: 2006-01-04 Impact factor: 24.094
Authors: Shuaib M Abdullah; Amit Khera; Sandeep R Das; Harold G Stanek; Russell M Canham; Anne K Chung; David A Morrow; Mark H Drazner; Darren K McGuire; James A de Lemos Journal: Am J Cardiol Date: 2005-09-09 Impact factor: 2.778
Authors: Torbjørn Omland; James A de Lemos; Marc S Sabatine; Costas A Christophi; Madeline Murguia Rice; Kathleen A Jablonski; Solve Tjora; Michael J Domanski; Bernard J Gersh; Jean L Rouleau; Marc A Pfeffer; Eugene Braunwald Journal: N Engl J Med Date: 2009-11-25 Impact factor: 91.245
Authors: Michael R Zile; Tom D Bennett; Martin St John Sutton; Yong K Cho; Philip B Adamson; Mark F Aaron; Juan M Aranda; William T Abraham; Frank W Smart; Lynne Warner Stevenson; Fred J Kueffer; Robert C Bourge Journal: Circulation Date: 2008-09-15 Impact factor: 29.690
Authors: Roberto Latini; Serge Masson; Inder S Anand; Emil Missov; Marjorie Carlson; Tarcisio Vago; Laura Angelici; Simona Barlera; Giovanni Parrinello; Aldo P Maggioni; Gianni Tognoni; Jay N Cohn Journal: Circulation Date: 2007-08-13 Impact factor: 29.690
Authors: James A de Lemos; Darren K McGuire; Amit Khera; Sandeep R Das; Sabina A Murphy; Torbjorn Omland; Mark H Drazner Journal: Am Heart J Date: 2009-02-20 Impact factor: 4.749
Authors: Erin J Howden; Satyam Sarma; Justin S Lawley; Mildred Opondo; William Cornwell; Douglas Stoller; Marcus A Urey; Beverley Adams-Huet; Benjamin D Levine Journal: Circulation Date: 2018-01-08 Impact factor: 29.690
Authors: Walter Oliver; Gwendolyn Matthews; Colby R Ayers; Sonia Garg; Sachin Gupta; Ian J Neeland; Mark H Drazner; Jarett D Berry; Susan Matulevicius; James A de Lemos Journal: Circ Cardiovasc Imaging Date: 2017-02 Impact factor: 7.792
Authors: Ambarish Pandey; Neil Keshvani; Colby Ayers; Adolfo Correa; Mark H Drazner; Alana Lewis; Carlos J Rodriguez; Michael E Hall; Ervin R Fox; Robert J Mentz; Christopher deFilippi; Stephen L Seliger; Christie M Ballantyne; Ian J Neeland; James A de Lemos; Jarett D Berry Journal: JAMA Cardiol Date: 2019-01-01 Impact factor: 14.676
Authors: Sonia Garg; James A de Lemos; Colby Ayers; Michel G Khouri; Ambarish Pandey; Jarett D Berry; Ronald M Peshock; Mark H Drazner Journal: JACC Cardiovasc Imaging Date: 2015-08-19